ideasIdea

Treat the body cavity, not the bloodstream, for surface spread

Intracavitary immunotherapy targets cancer that coats the lining of the abdomen or chest, which drugs given by drip barely reach. Delivering it straight into the cavity gives far higher local doses.

Peritoneal and pleural surface disease has poor drug penetration from the circulation, which is why intraperitoneal chemotherapy and pressurised aerosol delivery persist despite mixed evidence. Regional immunotherapy — intraperitoneal interleukin-2, checkpoint antibodies, T-cell engagers or CAR-T cells — reaches high local concentrations, and intrapleural mesothelin CAR-T has shown feasibility. The unresolved questions are dosing, drainage-related loss and cytokine toxicity.

Hypothesis

Intracavitary administration achieves at least tenfold higher local drug exposure than intravenous dosing at equal systemic exposure, and produces higher rates of cytological clearance of malignant effusion.

Rationale

Pharmacology strongly favours regional delivery for a compartmentalised disease, and cytological clearance provides a fast, objective, inexpensive endpoint. Regional cell therapy has already been shown to be safer than systemic in the pleural space.

What would test it

A pharmacokinetic and pharmacodynamic study comparing intracavitary with intravenous dosing of the same agent, with cytological clearance and paired compartment sampling as endpoints.

Maturity

early clinical

Who has to act

clinic

Cost to try

Medium ($1M to $50M)

Years to first evidence

Bottlenecks it attacks

Cold tumours and the immunosuppressive microenvironment · Most tumours keep the immune system out or asleep, so immunotherapy helps only a minority.
Metastasis is understood least and studied last · Metastasis causes about nine in ten cancer deaths but gets a small fraction of research money and almost no trials of its own.

Connected

12top

Pages like this

not linked directly; found by shared links

Idea
Peritoneal-directed therapy for gastric cancer
Shares Peritoneal metastasis, HIPEC / PIPAC (intraperitoneal chemotherapy), Metastasis is understood least and studied last, Gastric & gastro-oesophageal junction cancer.
Target
MUC16 (CA-125)
Shares Mesothelin, T-cell engagers (bispecific), Ovarian cancer, CAR-T cell therapy.
Person
Raffit Hassan
Shares Mesothelin, Mesothelioma.
Term
HIPEC (hyperthermic intraperitoneal chemotherapy)
Shares HIPEC / PIPAC (intraperitoneal chemotherapy), Ovarian cancer, Gastric & gastro-oesophageal junction cancer.
Institution
University Hospital Basel / Tumour Centre
Shares Metastasis is understood least and studied last, Ovarian cancer, CAR-T cell therapy, Immune checkpoint inhibitors.
Institution
Henan Cancer Hospital
Shares Gastric & gastro-oesophageal junction cancer, CAR-T cell therapy, Immune checkpoint inhibitors.
Institution
Taipei Veterans General Hospital
Shares Gastric & gastro-oesophageal junction cancer, CAR-T cell therapy, Immune checkpoint inhibitors.
Person
Philip D. Greenberg
Shares Mesothelin, CAR-T cell therapy.

Not yet reviewedNeeds expert (scientific) review. Review this page or see the review queue and roster.

ProvenanceLast edited 2026-09-09 · Jude Gomila · Editing pass: every TL;DR and summary stands alone · diff · file · history

Data

JSON · ·

Wrong or missing?

Propose a change with a source. Organisations can update their own records. Every suggestion is reviewed, safety-checked and validated before it goes live; nothing is edited directly.

Suggest an editDiscuss start a thread

Cancers

Technologies

Targets